NHS wins landmark High Court battle with two major drug firms

A judge rejected an action brought by Bayer and Novartis against 12 NHS clinical commissioning groups in north England relating to Avastin, an age-related macular degeneration drug.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

Abstract PURPOSE: To study the real-life outcomes of intravitreal anti-vascular endothelial growth factor treatment in patients affected by age-related macular degeneration and diabetic macular edema in an Italian tertiary referral hospital over a 2-year follow-up. METHODS: Patients with confirmed diagnosis of age-related macular degeneration or diabetic macular edema and 2 years of follow-up were retrospectively analyzed. They underwent a loading dose of three monthly anti-vascular endothelial growth factor injections, with re-treatment performed following a "pro-re-nata" regimen. Best-corre...
Source: European Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Eur J Ophthalmol Source Type: research
Publication date: Available online 14 October 2019Source: Orthopaedics &Traumatology: Surgery &ResearchAuthor(s): Patrice Mertl, Massinissa DehlAbstractFemoral stem modularity in hip replacement was first developed to connect a ceramic head to the stem, then extended to metal heads using the Morse taper principle. Is it a good thing, or a necessary evil? It contributes to improving lower limb length and lateralization setting, at the cost of fairly rare complications such as dissociation and fretting corrosion, which can exceptionally lead to ARMD (Adverse Reaction to Metal Debris). Modular necks were later recomme...
Source: Orthopaedics and Traumatology: Surgery and Research - Category: Orthopaedics Source Type: research
Condition:   Neovascular (Wet) Age-Related Macular Degeneration Interventions:   Drug: aflibercept;   Drug: High-Dose aflibercept Sponsors:   Regeneron Pharmaceuticals;   Bayer Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Kelsey Moody of Ichor Therapeutics presented on the LysoClear development program at the Ending Age-Related Diseases conference organized by the Life Extension Advocacy Foundation earlier this year. LysoClear is an example of the commercial development of a rejuvenation therapy, taken all the way from the starting point of the discovery of microbial enzymes capable of breaking down certain forms of harmful age-related molecular waste that contribute to aging and age-related diseases. The actual research is largely done, and the task now is to focus on manufacture, regulatory approval, and entry into the clinic. Take...
Source: Fight Aging! - Category: Research Authors: Tags: Healthy Life Extension Community Source Type: blogs
CONCLUSION: This report shows that sequentially treated nAMD fellow eyes have better baseline and final VA than non-sequentially treated eyes after 2 years of treatment. Sequentially treated eyes also had a greater proportion with good VA after 2 years. PMID: 31611234 [PubMed - as supplied by publisher]
Source: The British Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Br J Ophthalmol Source Type: research
Publication date: Available online 10 October 2019Source: Life SciencesAuthor(s): Pallavi Gupta, Khushwant S. YadavAbstractTreatment of majority of eye diseases involve the use of eye drops or eye ointments, which have major drawbacks of needing frequent administration, lower bioavailability and inability to cross the various eye barriers. This necessitates the use of novel delivery systems. Microneedles (MNs) as an alternate novel delivery system facilitate drug delivery to various ocular diseases with promising approaches in healthcare. Advances in pharmaceutical technology have made MNs provide localized, effective, les...
Source: Life Sciences - Category: Biology Source Type: research
NIH Director's Wednesday Afternoon Lecture Series Age-related macular degeneration (AMD) is the leading cause of blindness in the United States and in the developed world. Two NIH-supported randomized clinical trials with 10 years of follow-up in nearly 10,000 participants demonstrated that nutritional supplements with antioxidant vitamins and minerals reduces the risk of progression to late AMD. Dietary data suggest the importance of the Mediterranean diet in reducing the risk of AMD, particularly fish consumption. The analyses of the genetic interaction with nutrition challenges the idea that you can eat away your geneti...
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video
This case report describes an elderly man with neovascular age-related macular degeneration with a new spot on his eye.
Source: JAMA Ophthalmology - Category: Opthalmology Source Type: research
To report and compare 10-year treatment outcomes of vascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration (nAMD) from Australia and New Zealand (ANZ) and Switzerland.
Source: American Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Original Articles Source Type: research
To assess the prevalence of age-related macular degeneration (AMD) in a Russian population.
Source: American Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Original Articles Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Avastin | Health | Legislation